In This Article:
Repare Therapeutics has dosed the first subject in its Phase I POLAR clinical trial of RP-3467, a Polθ ATPase inhibitor, as a potential treatment for various solid tumours.
The POLAR trial is the fourth clinical programme of Repare.
The open-label, multicentre, dose-escalation Phase I trial aims to assess the safety, pharmacokinetics, pharmacodynamics and initial clinical activity of RP-3467.
RP-3467 will be administered alone or along with the PARP inhibitor olaparib to adults with molecularly selected advanced solid tumours.
Individuals with locally advanced or metastatic epithelial ovarian cancer, metastatic breast cancer, metastatic castration-resistant prostate cancer or pancreatic adenocarcinoma are eligible, and 52 will be enrolled in the study.
The trial's primary objective is to assess the safety and tolerability of RP-3467, both as a monotherapy and in combination with Olaparib.
The trial will also define a preliminary recommended Phase II dose of RP-3467 when used with olaparib.
Repare Therapeutics executive vice-president and chief medical officer Maria Koehler stated: “RP-3467, our potential best-in-class Polθ ATPase inhibitor, has demonstrated highly compelling preclinical results, including complete and durable tumour regressions in combination with olaparib, the leading PARP inhibitor, with no additive toxicities. This combination is designed to meaningfully improve patient outcomes by mitigating PARP inhibitor resistance, a significant area of high unmet medical need.
“In addition, Repare’s previously reported data established the potential for RP-3467 to improve efficacy and limit toxicity in combination with radioligand therapy and chemotherapy-bearing antibody-drug conjugates (ADCs), and we look forward to exploring those areas.”
In August 2024 the company announced plans to reduce its workforce by around 25% as it prioritises operations on its four clinical programmes in oncology indications and shuns new candidate discoveries.
"Repare Therapeutics doses first subject in Phase I solid tumour trial" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.